DexCom (NASDAQ: DXCM ) has outperformed the market over the past 5 years by 23.93% on an annualized basis producing an average annual return of 35.38%. Currently, DexCom has a market capitalization of $51.74 billion. Buying $1000 In DXCM: If an … Full story available on Benzinga.com

People are interested in ETFs for weight loss because of Oprah’s TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she’s talking to patients and doctors about using prescription drugs to lose weight, but it’s still causing a stir. It’s also big news that Oprah is leaving the Weight Watchers board . The fact that she backs drugs like Mounjaro, Wegovy and Ozempic shows how times are changing for everyone. It’s always been hard for the famous talk show host to lose weight. But because she was so famous, everything she suggested to lose weight sold out very quickly. In other words, we see the same pattern with drugs that help people lose weight. Because of Oprah’s ABC special , the dieting business and the practice of dieting are changing. This is like what happened when she really tried to lose weight in 1998. The only difference is the methodology she’s adopting. But be careful while Oprah fights the social shame that comes with losing weight with Ozempic.

EVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc (DXCM)

Insider Sell: DexCom Inc (DXCM) President, CEO and Chairman Kevin Sayer Sells 49,633 Shares

The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed’s stance on interest rate adjustments. Amid this climate, it’s essential to highlight a few potential Nasdaq stocks to sell. They could represent a shift from the buoyant sentiment a month ago when the Nasdaq and broader markets reached successive record highs. While returns have been strong year-to-date (YTD), some analysts argue that exuberance may be fading as the Nasdaq posted near double-digit gains in Q1. Expecting higher valuations to face corrections and better align with company fundamentals is reasonable. For context, the Nasdaq’s price-to-earnings multiple of 33.4 is at its highest since the dot-com bubble. This doesn’t imply there will be a definite turn, but it raises the prospects for certain Nasdaq stocks to sell as they have become overvalued. Should the Fed refrain from or delay expected rate cuts in June, higher borrowing costs could impact firms with high debt.

DexCom sees its Relative Strength Rating enter the 80-plus level.

DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy. “We are always working to advance the interests of our stakeholders, including our global Jetzt den vollständigen Artikel lesen

https://www.investing.com/news/press-releases/dexcom-schedules-first-quarter-2024-earnings-release-and-conference-call-for-april-25-2024-at-430-pm-eastern-time-93CH-3361765

BNN Bloomberg reported in July 2023 that the S&P 500 was overvalued by about 8%, according to Cresset Capital Chief Information Officer Jack Ablin. In the eight months since, it’s up another 19%, providing plenty of overvalued S&P 500 stocks to avoid. An excellent place to find these overvalued S&P 500 stocks is the Magnificent Seven. The index’s current trailing 12-month (TTM) price-to-earnings (P/E) ratio is 23.6x , while its forward 12-month P/E ratio is 21.6x. A year ago, the S&P 500’s TTM P/E was 18.1, 30% higher. Ablin did say last July that the average stock would probably perform well despite the index’s excessive valuation. That’s changed with the higher P/E. As of March 5, 2024, the Magnificent Seven’s TTM P/E was 38.5x , 38% lower, while the S&P 500 Equal Weight Index was 20.6x, 16% cheaper than the market cap-weighted version. To make my list of three overvalued S&P 500 stocks, it can’t be one of the Magnificent Seven and it should have a TTM P/E higher than its current ratio of 23.6x.